Platelet transfusion therapy

Hematology/Oncology Clinics of North America

Volumn 27, Issue 3, 2013, Pages 629-643

  Thiagarajan, Perumal ^a   Afshar Kharghan, Vahid ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Alloimmunization; Pathogen reduction; Platelet transfusion; Transfusion triggers

Indexed keywords

ADRENALIN; CORTICOSTEROID; DIPHENHYDRAMINE; HYPERTENSIVE FACTOR; THROMBOCYTE CONCENTRATE;

ALLERGIC REACTION; ALLOIMMUNIZATION; ANAPHYLAXIS; BACTERIAL INFECTION; BLEEDING; BLOOD BUFFY COAT; BLOOD TRANSFUSION REACTION; DONOR; HUMAN; HYPERVOLEMIA; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; THROMBOCYTE LIFESPAN; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPHERESIS; TRANSFUSION RELATED ACUTE LUNG INJURY; VIRUS INFECTION;

BLOOD PLATELETS; HUMANS; PLATELET TRANSFUSION; SPECIMEN HANDLING;

EID: 84878216474     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.03.004     Document Type: Review

References (103)

1. Duke W.W. The relation of blood platelets to hemorrhagic disease. JAMA 1983, 250:1201-1209.
2. Gaydos L.A., Freireich E.J., Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962, 266:905-909.
3. Freireich E.J. Origins of platelet transfusion therapy. Transfus Med Rev 2011, 25:252-256.
4. Murphy S., Gardner F.H. Platelet storage at 22 degrees C: role of gas transport across plastic containers in maintenance of viability. Blood 1975, 46:209-218.
5. Filip D.J., Aster R.H. Relative hemostatic effectiveness of human platelets stored at 4 degrees and 22 degrees C. J Lab Clin Med 1978, 91:618-624.
6. Slichter S.J. Preservation of platelet viability and function during storage of concentrates. Prog Clin Biol Res 1978, 28:83-100.
7. Hanson S.R., Slichter S.J. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood 1985, 66:1105-1109.
8. Rand M.L., Wang H., Bang K.W., et al. Procoagulant surface exposure and apoptosis in rabbit platelets: association with shortened survival and steady-state senescence. J Thromb Haemost 2004, 2:651-659.
9. Pereira J., Palomo I., Ocqueteau M., et al. Platelet aging in vivo is associated with loss of membrane phospholipid asymmetry. Thromb Haemost 1999, 82:1318-1321.
10. Schlegel R.A., Callahan M.K., Williamson P. The central role of phosphatidylserine in the phagocytosis of apoptotic thymocytes. Ann N Y Acad Sci 2000, 926:217-225.
11. Zwaal R.F., Schroit A.J. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997, 89:1121-1132.
12. Thiagarajan P., Tait J.F. Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J Biol Chem 1990, 265:17420-17423.
13. Schoenwaelder S.M., Yuan Y., Josefsson E.C., et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 2009, 114:663-666.
14. Lotter M.G., Heyns A.D., Badenhorst P.N., et al. Evaluation of mathematic models to assess platelet kinetics. J Nucl Med 1986, 27:1192-1201.
15. Dowling M.R., Josefsson E.C., Henley K.J., et al. Platelet senescence is regulated by an internal timer, not damage inflicted by hits. Blood 2010, 116:1776-1778.
16. Zhang H., Nimmer P.M., Tahir S.K., et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007, 14:943-951.
17. Bertino A.M., Qi X.Q., Li J., et al. Apoptotic markers are increased in platelets stored at 37 degrees C. Transfusion 2003, 43:857-866.
18. Mason K.D., Carpinelli M.R., Fletcher J.I., et al. Programmed anuclear cell death delimits platelet life span. Cell 2007, 128:1173-1186.
19. Dasgupta S.K., Argaiz E.R., Mercado J.E., et al. Platelet senescence and phosphatidylserine exposure. Transfusion 2010, 50:2167-2175.
20. Lo S.K., Burhop K.E., Kaplan J.E., et al. Role of platelets in maintenance of pulmonary vascular permeability to protein. Am J Physiol 1988, 254:H763-H771.
21. Aursnes I. Increased permeability of capillaries to protein during thrombocytopenia. An experimental study in the rabbit. Microvasc Res 1974, 7:283-295.
22. Gimbrone M.A., Aster R.H., Cotran R.S., et al. Preservation of vascular integrity in organs perfused in vitro with a platelet-rich medium. Nature 1969, 222:33-36.
23. McDonagh P.F. Platelets reduce coronary microvascular permeability to macromolecules. Am J Physiol 1986, 251:H581-H587.
24. Cauwenberghs S., van Pampus E., Curvers J., et al. Hemostatic and signaling functions of transfused platelets. Transfus Med Rev 2007, 21:287-294.
25. Rao A.K., Murphy S. Secretion defect in platelets stored at 4 degrees C. Thromb Haemost 1982, 47:221-225.
26. Rao A.K., Niewiarowski S., Murphy S. Acquired granular pool defect in stored platelets. Blood 1981, 57:203-208.
27. Murphy S. Radiolabeling of PLTs to assess viability: a proposal for a standard. Transfusion 2004, 44:131-133.
28. Shapira S., Friedman Z., Shapiro H., et al. The effect of storage on the expression of platelet membrane phosphatidylserine and the subsequent impacton the coagulant function of stored platelets. Transfusion 2000, 40:1257-1263.
29. Perrotta P.L., Perrotta C.L., Snyder E.L. Apoptotic activity in stored human platelets. Transfusion 2003, 43:526-535.
30. Hoffmeister K.M., Josefsson E.C., Isaac N.A., et al. Glycosylation restores survival of chilled blood platelets. Science 2003, 301:1531-1534.
31. Wandall H.H., Hoffmeister K.M., Sorensen A.L., et al. Galactosylation does not prevent the rapid clearance of long-term, 4 degrees C-stored platelets. Blood 2008, 111:3249-3256.
32. Murphy S. Platelets from pooled buffy coats: an update. Transfusion 2005, 45:634-639.
33. Schiffer C.A., Aisner J., Dutcher J.P., et al. A clinical program of platelet cryopreservation. Prog Clin Biol Res 1982, 88:165-180.
34. Johnson L.N., Winter K.M., Reid S., et al. Cryopreservation of buffy-coat-derived platelet concentrates in dimethyl sulfoxide and platelet additive solution. Cryobiology 2011, 62:100-106.
35. Palavecino E.L., Yomtovian R.A., Jacobs M.R. Bacterial contamination of platelets. Transfus Apher Sci 2010, 42:71-82.
36. Dumont L.J., Kleinman S., Murphy J.R., et al. Screening of single-donor apheresis platelets for bacterial contamination: the PASSPORT study results. Transfusion 2010, 50:589-599.
37. Blajchman M.A., Beckers E.A., Dickmeiss E., et al. Bacterial detection of platelets: current problems and possible resolutions. Transfus Med Rev 2005, 19:259-272.
38. Reesink H.W., Panzer S., McQuilten Z.K., et al. Pathogen inactivation of platelet concentrates. Vox Sang 2010, 99:85-95.
39. Lozano M., Knutson F., Tardivel R., et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011, 153:393-401.
40. Seghatchian J., de Sousa G. Pathogen-reduction systems for blood components: the current position and future trends. Transfus Apher Sci 2006, 35:189-196.
41. Seghatchian J., Tolksdorf F. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update. Transfus Apher Sci 2012, 46:221-229.
42. Rebulla P., Finazzi G., Marangoni F., et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 1997, 337:1870-1875.
43. Slichter S.J. Evidence-based platelet transfusion guidelines. Hematology Am Soc Hematol Educ Program 2007, 172-178.
44. Schiffer C.A., Anderson K.C., Bennett C.L., et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19:1519-1538.
45. Guidelines for the use of platelet transfusions. Br J Haematol 2003, 122:10-23.
46. Gmur J., Burger J., Schanz U., et al. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 1991, 338:1223-1226.
47. Falanga A., Rickles F.R. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003, 16:463-482.
48. McCullough J. Overview of platelet transfusion. Semin Hematol 2010, 47:235-242.
49. Valeri C.R., Khuri S., Ragno G. Nonsurgical bleeding diathesis in anemic thrombocytopenic patients: role of temperature, red blood cells, platelets, and plasma-clotting proteins. Transfusion 2007, 47:206S-248S.
50. Valeri C.R., Cassidy G., Pivacek L.E., et al. Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss. Transfusion 2001, 41:977-983.
51. Heddle N.M., Cook R.J., Tinmouth A., et al. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009, 113:1564-1573.
52. Sensebe L., Giraudeau B., Bardiaux L., et al. The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study. Blood 2005, 105:862-864.
53. Stefanich E., Senn T., Widmer R., et al. Metabolism of thrombopoietin (TPO) in vivo: determination of the binding dynamics for TPO in mice. Blood 1997, 89:4063-4070.
54. Slichter S.J., Kaufman R.M., Assmann S.F., et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010, 362:600-613.
55. Triulzi D.J., Assmann S.F., Strauss R.G., et al. The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood 2012, 119:5553-5562.
56. Shehata N., Tinmouth A., Naglie G., et al. ABO-identical versus nonidentical platelet transfusion: a systematic review. Transfusion 2009, 49:2442-2453.
57. Friedmann A.M., Sengul H., Lehmann H., et al. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev 2002, 16:34-45.
58. Stanworth S.J., Dyer C., Choo L., et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfus Med Rev 2010, 24:163-171.
59. Woodman R.C., Harker L.A. Bleeding complications associated with cardiopulmonary bypass. Blood 1990, 76:1680-1697.
60. Stramer S.L., Wend U., Candotti D., et al. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 2011, 364:236-247.
61. Perrotta P.L., Snyder E.L. Non-infectious complications of transfusion therapy. Blood Rev 2001, 15:69-83.
62. Vassallo R.R. Review: IgA anaphylactic transfusion reactions. Part I. Laboratory diagnosis, incidence, and supply of IgA-deficient products. Immunohematology 2004, 20:226-233.
63. Shimada E., Tadokoro K., Watanabe Y., et al. Anaphylactic transfusion reactions in haptoglobin-deficient patients with IgE and IgG haptoglobin antibodies. Transfusion 2002, 42:766-773.
64. Lambin P., Le Pennec P.Y., Hauptmann G., et al. Adverse transfusion reactions associated with a precipitating anti-C4 antibody of anti-Rodgers specificity. Vox Sang 1984, 47:242-249.
65. Yazer M.H., Podlosky L., Clarke G., et al. The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion 2004, 44:10-15.
66. Hillyer C.D., Josephson C.D., Blajchman M.A., et al. Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. Hematology Am Soc Hematol Educ Program 2003, 575-589.
67. Heddle N.M. Pathophysiology of febrile nonhemolytic transfusion reactions. Curr Opin Hematol 1999, 6:420-426.
68. Heddle N.M., Klama L., Singer J., et al. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994, 331:625-628.
69. Riccardi D., Raspollini E., Rebulla P., et al. Relationship of the time of storage and transfusion reactions to platelet concentrates from buffy coats. Transfusion 1997, 37:528-530.
70. Winqvist I. Meperidine (pethidine) to control shaking chills and fever associated with non-hemolytic transfusion reactions. Eur J Haematol 1991, 47:154-155.
71. McCarthy L.J., Danielson C.F., Miraglia C., et al. Platelet transfusion and thrombotic thrombocytopenic purpura. Transfusion 2003, 43:829. [author reply: 829-30].
72. Harkness D.R., Byrnes J.J., Lian E.C., et al. Hazard of platelet transfusion in thrombotic thrombocytopenic purpura. JAMA 1981, 246:1931-1933.
73. Gordon L.I., Kwaan H.C., Rossi E.C. Deleterious effects of platelet transfusions and recovery thrombocytosis in patients with thrombotic microangiopathy. Semin Hematol 1987, 24:194-201.
74. de la Rubia J., Plume G., Arriaga F., et al. Platelet transfusion and thrombotic thrombocytopenic purpura. Transfusion 2002, 42:1384-1385.
75. Swisher K.K., Terrell D.R., Vesely S.K., et al. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion 2009, 49:873-887.
76. Refaai M.A., Chuang C., Menegus M., et al. Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia. J Thromb Haemost 2010, 8:1419-1421.
77. Daly P.A., Schiffer C.A., Aisner J., et al. Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations. JAMA 1980, 243:435-438.
78. Rebulla P. A mini-review on platelet refractoriness. Haematologica 2005, 90:247-253.
79. Hod E., Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008, 142:348-360.
80. Doughty H.A., Murphy M.F., Metcalfe P., et al. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994, 66:200-205.
81. Slichter S.J., Davis K., Enright H., et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005, 105:4106-4114.
82. Datema G., Stein S., Eijsink C., et al. HLA-C expression on platelets: studies with an HLA-Cw1-specific human monoclonal antibody. Vox Sang 2000, 79:108-111.
83. Carr R., Hutton J.L., Jenkins J.A., et al. Transfusion of ABO-mismatched platelets leads to early platelet refractoriness. Br J Haematol 1990, 75:408-413.
84. Detection of platelet-reactive antibodies in patients who are refractory to platelet transfusions, and the selection of compatible donors. Vox Sang 2003, 84:73-88.
85. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997, 337:1861-1869.
86. Pavenski K., Freedman J., Semple J.W. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. Tissue Antigens 2012, 79:237-245.
87. Seftel M.D., Growe G.H., Petraszko T., et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004, 103:333-339.
88. Asano H., Lee C.Y., Fox-Talbot K., et al. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007, 84:1174-1182.
89. Jackman R.P., Heitman J.W., Marschner S., et al. Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment. Transfusion 2009, 49:2686-2699.
90. Moroff G., George V.M., Siegl A.M., et al. The influence of irradiation on stored platelets. Transfusion 1986, 26:453-456.
91. Duquesnoy R.J., Filip D.J., Rodey G.E., et al. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol 1977, 2:219-226.
92. Bolgiano D.C., Larson E.B., Slichter S.J. A model to determine required pool size for HLA-typed community donor apheresis programs. Transfusion 1989, 29:306-310.
93. Grishaber J.E., Birney S.M., Strauss R.G. Potential for transfusion-associated graft-versus-host disease due to apheresis platelets matched for HLA class I antigens. Transfusion 1993, 33:910-914.
94. Duquesnoy R.J. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. I. Description of the algorithm. Hum Immunol 2002, 63:339-352.
95. Nambiar A., Duquesnoy R.J., Adams S., et al. HLAMatchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients. Blood 2006, 107:1680-1687.
96. Kickler T.S., Braine H., Ness P.M. The predictive value of crossmatching platelet transfusion for alloimmunized patients. Transfusion 1985, 25:385-389.
97. Sintnicolaas K., Lowenberg B. A flow cytometric platelet immunofluorescence crossmatch for predicting successful HLA matched platelet transfusions. Br J Haematol 1996, 92:1005-1010.
98. Gelb A.B., Leavitt A.D. Crossmatch-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets. Transfusion 1997, 37:624-630.
99. Petz L.D., Garratty G., Calhoun L., et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion 2000, 40:1446-1456.
100. Levin M.D., van der Holt B., de Veld J.C., et al. The value of crossmatch tests and panel tests as a screening tool to predict the outcome of platelet transfusion in a non-selected haematological population of patients. Vox Sang 2004, 87:291-298.
101. Josephson C.D., Glynn S.A., Kleinman S.H., et al. A multidisciplinary "think tank" : the top 10 clinical trial opportunities in transfusion medicine from the National Heart, Lung, and Blood Institute-sponsored 2009 state-of-the-science symposium. Transfusion 2011, 51:828-841.
102. Blajchman M.A. Substitutes and alternatives to platelet transfusions in thrombocytopenic patients. J Thromb Haemost 2003, 1:1637-1641.
103. Takayama N., Nishikii H., Usui J., et al. Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. Blood 2008, 111:5298-5306.